{
  "ticker": "JNJ",
  "target_date": "2025-03-11",
  "actual_date": "2025-03-11",
  "collected_at": "2025-12-08T11:30:09.166791",
  "price": {
    "open": 163.53,
    "high": 163.63,
    "low": 161.43,
    "close": 162.22190856933594,
    "volume": 9890300,
    "change_1d_pct": -1.1,
    "change_7d_pct": 0.51,
    "change_30d_pct": 9.35
  },
  "technicals": {
    "rsi_14": 68.12,
    "sma_20": 158.46,
    "sma_50": 149.49,
    "macd": 4.002,
    "macd_signal": 4.079,
    "macd_histogram": -0.077,
    "bb_upper": 167.85,
    "bb_lower": 149.06,
    "price_vs_sma20_pct": 2.37,
    "price_vs_sma50_pct": 8.51,
    "volume_ratio": 0.99
  },
  "fundamentals": {
    "market_cap": 488930312192,
    "pe_ratio": 19.588322,
    "forward_pe": 19.14481,
    "price_to_book": 6.159438,
    "price_to_sales": 5.3058667,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.35,
    "pct_from_52w_low": 44.25
  },
  "macro": {
    "spy": {
      "price": 551.09,
      "change_1d_pct": -0.83,
      "change_7d_pct": -4.77
    },
    "vix": {
      "level": 26.92,
      "signal": "HIGH_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.29
    },
    "dollar_index": {
      "level": 103.44
    },
    "gold": {
      "price": 2912.9
    },
    "regime": "BEAR_HIGH_VOL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson (NYSE:JNJ) Reports Positive Phase 2b Trial Results For Ulcerative Colitis Treatment",
      "source": "Yahoo",
      "datetime": 1741714590,
      "summary": "Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant announcements regarding its clinical trials, particularly the ANTHEM-UC study, which showcased promising results in ulcerative colitis treatment. These positive results provide",
      "url": "https://finnhub.io/api/news?id=dbfce4c852824063f9db499eb83b0e2d015f5525e6bf3b6bd7439bb5f77f24c3"
    },
    {
      "headline": "Legend Biotech's Carvykti Is Taking Off, And It's Still Early (Rating Upgrade)",
      "source": "SeekingAlpha",
      "datetime": 1741710774,
      "summary": "Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click for my updated look at LEGN earnings.",
      "url": "https://finnhub.io/api/news?id=9f1910c5e487ba2c0ff679899a263343373f86252cee9e7c7170cdfe7c22f59d"
    },
    {
      "headline": "PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study",
      "source": "Yahoo",
      "datetime": 1741709700,
      "summary": "The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.",
      "url": "https://finnhub.io/api/news?id=51d6b6a1088bc2bbd46313bd614410d7fa56bacd4c5f21889dfcea00d570df1a"
    },
    {
      "headline": "Is Johnson & Johnson (JNJ) the Best Low Risk Stock to Buy In 2025?",
      "source": "Yahoo",
      "datetime": 1741709274,
      "summary": "We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other low risk stocks. Risk is a key consideration in investing and portfolio management, as investors generally aim to ach",
      "url": "https://finnhub.io/api/news?id=8022d6dfccade734b4ea6607990bf0cf80a76ace195eeadc7dc256e0a6737b58"
    },
    {
      "headline": "Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It",
      "source": "SeekingAlpha",
      "datetime": 1741708809,
      "summary": "Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis. Click fo rmy PTGX update.",
      "url": "https://finnhub.io/api/news?id=9e0337c08ddb883be885c55f1206f206b8fb08bfd2f83fd9ca8c00378b311f90"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-06",
      "description": "xslF345X05/wk-form4_1741297319.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000095/xslF345X05/wk-form4_1741297319.xml"
    },
    {
      "form": "4",
      "date": "2025-03-06",
      "description": "xslF345X05/wk-form4_1741297124.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000093/xslF345X05/wk-form4_1741297124.xml"
    },
    {
      "form": "4",
      "date": "2025-02-26",
      "description": "xslF345X05/wk-form4_1740613359.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000086/xslF345X05/wk-form4_1740613359.xml"
    },
    {
      "form": "8-K",
      "date": "2025-02-26",
      "description": "d863514d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525036773/d863514d8k.htm"
    },
    {
      "form": "8-K",
      "date": "2025-02-20",
      "description": "d866332d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525030851/d866332d8k.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}